Motor Neuron Disease
96
21
23
44
Key Insights
Highlights
Success Rate
85% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
8.3%
8 terminated out of 96 trials
84.6%
-1.9% vs benchmark
3%
3 trials in Phase 3/4
16%
7 of 44 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 44 completed trials
Clinical Trials (96)
IC14 for Treatment of Amyotrophic Lateral Sclerosis
Electrical Impedance Myography: Natural History Studies inNeuromuscular Disorders and Healthy Volunteers
Study of Predictive Factors of Progression of Motor Neurone Disease
Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)
Non-invasive BCI-controlled Assistive Devices
INdependence Through Endovascular Neuroprosthetic Technology (INTENT): an Early Feasibility Study
Functional Outcomes and Control Using Synchron BCI - Canada
Functional Outcomes and Control Using Synchron BCI - Australia
Study of Inherited Neurological Disorders
Impact of Physical Functioning on Patient-Reported Outcomes in ALS Patients at TidalHealth
Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)
Clinical, Molecular and Imaging Biomarkers in Spinal and Bulbar Muscular Atrophy (SBMA)
Development and Test of a Headset for BCI Until Obtaining an Efficient and Comfortable System That Can be Used in Daily Practice by ALS People
Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures
Digital App for Speech & Health Monitoring
Effects of Long Term Ventilation Support on the Quality of Life of ALS Patients and Their Families
Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease
GB-PRIME: An Early Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices
Safety of Intrathecal Riluzole in Patients With Amyotrophic Lateral Sclerosis
A Safety and Tolerability Study of ILB® in Patients With Amyotrophic Lateral Sclerosis (ALS)